Overview

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

A prospective, multicenter, open label, randomized phase III study to evaluate efficacy and safety of FFX versus CPI-613 + mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years

Phase:

Phase 3

Details

Lead Sponsor:

Rafael Pharmaceuticals Inc.

Treatments:

Camptothecin
Folfirinox
Folic Acid
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin
Pancrelipase